NERIO THERAPEUTICS
Nerio Therapeutics is a biotechnology company focused on the life sciences sector. It was founded in 2019 and is based in La Jolla, CA, USA.
NERIO THERAPEUTICS
Industry:
Biotechnology Life Science Therapeutics
Founded:
2019-01-01
Address:
La Jolla, California, United States
Country:
United States
Total Employee:
1+
Status:
Active
Total Funding:
6.5 M USD
Similar Organizations
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Tactile Therapeutics
Tactile Therapeutics is a biotechnology company that serves the life science industry.
Werewolf Therapeutics
Werewolf Therapeutics operates as an oncology biotherapeutics company.
Current Employees Featured
Founder
More informations about "Nerio Therapeutics"
Nerio Therapeutics - Crunchbase Company Profile & Funding
Nerio Therapeutics is a biotechnology company focused on the life sciences sector. It was founded in 2019 and is based in La Jolla, CA, USA. Nerio Therapeutics was acquired by …See details»
Boehringer Ingelheim acquires Nerio Therapeutics | Boehringer …
Jul 29, 2024 · Today marks a significant step for Boehringer Ingelheim’s immuno-oncology pipeline as the company is adding an innovative preclinical program with the acquisition of …See details»
Nerio Therapeutics Company Profile 2024: Valuation, …
Operator of a biopharmaceutical company intended to empower phosphatase drug discovery for immunotherapy.See details»
Boehringer Ingelheim acquires Nerio Therapeutics for …
Jul 30, 2024 · Boehringer Ingelheim has acquired drug discovery and development company Nerio Therapeutics in a $1.3bn deal. The acquisition bolsters Boehringer’s immuno-oncology pipeline with Nerio’s new PTPN2/N1 …See details»
Boehringer inks $1.3B acquisition of Nerio and its preclinical ...
Jul 29, 2024 · Boehringer Ingelheim is offering up to $1.3 billion for Nerio Therapeutics and a preclinical immune checkpoint inhibitor program that the German pharma giant hopes will …See details»
Nerio Therapeutics, A Viva Biotech's Portfolio Company, Was ...
Today marks a significant step for Boehringer Ingelheim's immuno-oncology pipeline as the company is adding an innovative preclinical program with the acquisition of Nerio Therapeutics …See details»
Boehringer Ingelheim Acquires Nerio Therapeutics
Jul 29, 2024 · Boehringer Ingelheim has acquired Nerio Therapeutics Inc. for a total of up to $1.3 billion. It aims to develop Nerio's innovative preclinical program as a potential key centerpiece …See details»
Boehringer Ingelheim acquires oncology biotech firm …
Aug 8, 2024 · Germany-based biotech firm Boehringer Ingelheim, which has its U.S. headquarters in Ridgefield, has acquired Nerio Therapeutics Inc., aCalifornia-based oncology biotech, for $1.3 billion, the...See details»
Boehringer Ingelheim to buy Nerio Therapeutics
Aug 5, 2024 · Pharmaceutical giant Boehringer Ingelheim is slated to buy the start-up Nerio Therapeutics in a deal worth up to $1.3 billion. With the acquisition, the firm gains a handful of …See details»
Boehringer Ingelheim acquires Nerio Therapeutics for …
Jul 29, 2024 · In a move to strengthen its immuno-oncology pipeline, Boehringer Ingelheim is acquiring Nerio Therapeutics for a total of up to $1.3 billion. “Securing the rights to Nerio Therapeutics’ novel checkpoint inhibitors creates …See details»
Nerio Therapeutics Sells to Boehringer Ingelheim for up to $1.
San Diego – July 29, 2024 – Cooley advised Nerio Therapeutics, a drug discovery and development company focused on phosphatases, a notoriously difficult class of potentially …See details»
Nerio Therapeutics - Funding, Financials, Valuation & Investors
Nerio Therapeutics is a biotechnology company focused on the life sciences sector.See details»
Boehringer buys oncology player Nerio in $1.3bn deal
Jul 30, 2024 · California, US-based Nerio is developing a series of small-molecule checkpoint inhibitors designed to rev up the immune system to fight cancers, focusing on compounds that …See details»
Boehringer adds to cancer drug pipeline with deal for startup Nerio
Jul 29, 2024 · Boehringer Ingelheim is investing again in immuno-oncology, announcing Monday a deal to acquire the San Diego-based biotechnology startup Nerio Therapeutics and its slate …See details»
Boehringer Buys Nerio Therapeutics for $1.3B to Boost Immuno
Jul 29, 2024 · Boehringer Ingelheim announced Monday that it has acquired Nerio Therapeutics and its preclinical program of novel immune checkpoint inhibitors for up to $1.3 billion to …See details»
Boehringer Ingelheim secures novel immune checkpoint inhibitor …
Jul 30, 2024 · Today marks a significant step for Boehringer Ingelheim’s immuno-oncology pipeline as the company is adding an innovative preclinical program with the acquisition of …See details»
Firm Advises Nerio on IP Matters Related to $1.3 Billion …
On July 29, 2024, biopharmaceutical company Boehringer Ingelheim announced its acquisition of Nerio Therapeutics, a drug discovery and development company focused on phosphatases, a …See details»
Boehringer buying Nerio for $1.3B for checkpoint inhibitors
Jul 30, 2024 · The German company is bolstering its cancer programs with the Nerio acquisition, which will be added to multibillion-dollar deals cut earlier this year for cancer immunotherapies …See details»
Boehringer Ingelheim buys Nerio Therapeutic for $1.3B - VatorNews
Jul 29, 2024 · Founded in 2019, and based in La Jolla, California, Nerio Therapeutics' small molecules inhibit the protein tyrosine phosphatases N1 and N2 (PTPN1 and PTPN2), which …See details»
Boehringer Acquires Nerio with Its Novel Checkpoint Inhibitors for …
Jul 30, 2024 · Yesterday, Boehringer Ingelheim announced it is acquiring Nerio Therapeutics, which has novel checkpoint inhibitors, for up to $1.3 billion. The pharma company aims to …See details»